title: Arterial repair 4 months after zotarolimus-eluting stent implantation observed on angioscopy.
abstract: BACKGROUND
  Arterial repair in the early phase following implantation of a zotarolimus-eluting stent (ZES) remains unknown.
  
  
  RESULTS
  Following implantation of 49 Endeavor ZES in 33 patients, follow-up angioscopy was performed in 13 patients (26 ZES) in the early phase (EP; 123±24 days) and in 20 patients (23 ZES) in the middle phase (MP; 247±17 days). Neointimal coverage (NIC) was graded as follows: grade 0, stent struts exposed; grade 1, struts bulging into the lumen, although covered; grade 2, struts were embedded by the neointima but were seen translucently; grade 3, struts fully embedded and invisible. NIC was defined as heterogeneous for NIC grade variation≥1. The presence of thrombus and yellow plaque was also investigated. Although NIC heterogeneity tended to be more frequent in EP than in MP (50% vs. 22%, P=0.070), and yellow plaque significantly more frequent (58% vs. 13%, P=0.0025), the majority of stents were dominant NIC grade 3 at both follow-up periods (73% in EP vs. 78% in MP, P=0.75). There was no significant difference in thrombus (23% in EP vs. 4% in MP, P=0.10) between the follow-ups.
  
  
  CONCLUSIONS
  Sufficient arterial repair may have occurred by 4 months after ZES implantation.
authors: Kansai Rosai Hospital Cardiovascular Center, Amagasaki, Japan.
authors: Takayuki
authors: T
authors: Ishihara
authors: Masaki
authors: M
authors: Awata
authors: Fusako
authors: F
authors: Sera
authors: Masashi
authors: M
authors: Fujita
authors: Tetsuya
authors: T
authors: Watanabe
authors: Osamu
authors: O
authors: Iida
authors: Yoshio
authors: Y
authors: Ishida
authors: Shinsuke
authors: S
authors: Nanto
authors: Masaaki
authors: M
authors: Uematsu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D017546:Angioscopy; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D016009:Chi-Square Distribution; D017023:Coronary Angiography; D003328:Coronary Thrombosis / Q000209:etiology / Q000473:pathology; D003331:Coronary Vessels / Q000000981:diagnostic imaging / Q000473:pathology*; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D058426:Neointima; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation*; D011237:Predictive Value of Tests; D011474:Prosthesis Design; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; C489443:zotarolimus; D020123:Sirolimus